CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
This is the first update to the original CTS communication distributed on July 6th. As previously co...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...